Agence France-Presse13 小时
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment ...
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase ...
Le Lézard15 小时
U.S. FDA Grants Full Approval of Deciphera's ROMVIMZAtm (vimseltinib) for the Treatment of ...
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; "Ono") announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZAtm (vimseltinib), a kinase ...
Karolinska Development AB: Year-end Report - January-December 2024
Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website. "Stronger ...
生物通12 小时
重大突破！胆囊癌全长转录组图谱揭示 ERBB2 可变剪接介导曲妥珠单抗 ...
为解决胆囊癌靶向治疗耐药问题，上海交通大学医学院附属仁济医院的研究人员开展胆囊癌转录组研究。他们发现 ERBB2 i14e 致曲妥珠单抗耐药，干预它可增敏。该成果为胆囊癌治疗提供新思路，强烈推荐科研读者阅读。